NASDAQ:PPH VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News $88.59 +1.07 (+1.22%) As of 11:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About VanEck Pharmaceutical ETF (NASDAQ:PPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PPH alerts:Sign Up Key Stats Today's Range$88.26▼$88.6450-Day Range$82.76▼$91.7852-Week Range$77.67▼$99.51Volume87,272 shsAverage Volume294,531 shsMarket Capitalization$495.22 millionAssets Under Management$498.07 millionDividend Yield2.20%Net Expense Ratio0.36%Aggregate RatingModerate Buy ETF Overview The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck. Read More VanEck Pharmaceutical ETF ExpensesTypePPHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.35%0.56%0.56%0.54%0.53%Other Expenses0.01%0.47%0.56%0.52%0.56%Total Expense0.36%0.75%0.76%0.73%0.73%Fee Waiver0.00%-0.67%-0.66%-0.50%-0.63%Net Expense0.36%0.60%0.63%0.63%0.60% Receive PPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address PPH ETF News HeadlinesJ&J rallies big pharma after earnings despite Trump’s latest tariff threatJuly 16, 2025 | msn.comPPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And CenterJuly 7, 2025 | seekingalpha.com🚀 3 Crypto Picks Every Growth Investor Should See (Free Ebook)Are you curious about how experienced investors approach crypto? Our free 30‑page ebook, Crypto Boom Strategy, outlines a three‑step framework they use to navigate the market, ideal for those with a growth-focused mindset.July 23 at 2:00 AM | StockEarnings (Ad)VanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.6069July 1, 2025 | msn.comGlobal pharma stocks down as Trump renews tariff threatJune 17, 2025 | msn.comPPH, Big Pharma Stocks Volatile on Trump Drug PricingMay 14, 2025 | finance.yahoo.comSee More Headlines PPH ETF - Frequently Asked Questions How have PPH shares performed this year? VanEck Pharmaceutical ETF's stock was trading at $86.28 on January 1st, 2025. Since then, PPH stock has increased by 1.4% and is now trading at $87.52. Who are VanEck Pharmaceutical ETF's major shareholders? Top institutional shareholders of VanEck Pharmaceutical ETF include Adamsbrown Wealth Consultants LLC (2.82%), Prime Capital Investment Advisors LLC (1.73%), AAFMAA Wealth Management & Trust LLC (0.64%) and NTV Asset Management LLC (0.13%). How do I buy shares of VanEck Pharmaceutical ETF? Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VanEck Pharmaceutical ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Pharmaceutical ETF investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssuerVan Eck Fund NameVanEck Pharmaceutical ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:PPH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkMVIS US Listed Pharmaceutical 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Number of Holdings25 Fund Statistics Assets Under Management$492.64 million Average Daily Volume$445.03 thousand Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianState Street Bank and Trust Company DistributorVan Eck Securities Corporation Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerIMC Options OptionableOptionable Options Volume60 Put Options30 Call Options30 Short Interest2,570,000 shs Miscellaneous Outstanding Shares5,590,000Beta0.72 Creation Unit50,000 Creation Fee$500.00 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 PPH HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 18.99%Johnson & Johnson (NYSE:JNJ)Holding Weight: 10.00%Novartis AG ADRHolding Weight: 7.59%Novo Nordisk A/S (NYSE:NVO)Holding Weight: 7.43%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 5.84%McKesson (NYSE:MCK)Holding Weight: 4.67%Pfizer (NYSE:PFE)Holding Weight: 4.60%AbbVie (NYSE:ABBV)Holding Weight: 4.53%Sanofi (NASDAQ:SNY)Holding Weight: 4.52%AstraZeneca (NASDAQ:AZN)Holding Weight: 4.41%Full Holdings Details This page (NASDAQ:PPH) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Pharmaceutical ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
